Clinical Trial

Barriers and Facilitators of Persistence With Adjuvant Osimertinib

Study acronym: SECURE
Not Yet Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated May 14, 2026 (before its estimated August 15, 2026 completion). Its status may not reflect the trial's current state.
Summary
This is a cross-sectional, non-interventional qualitative study using individual interviews to investigate determinants of persistence with 3rd generation EGFR-TKI osimertinib as adjuvant therapy among patients with early-stage NSCLC in China. Approximately 100 participants will be enrolled, comprising around 85 patients and 15 physicians. All participants will be interviewed online or in-person using a COM-B (Capability, Opportunity, Motivation - Behaviour) based guide. Interviews will be conducted in waves, recorded, transcribed, and analysed using both deductive and inductive methods.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2026-04-14.
Trial Details
NCT Number NCT07542210
Lead Sponsor AstraZeneca
Conditions Non-small Cell Lung Cancer
Enrollment 100 participants
Start Date 2026-06-01
Primary Completion 2026-08-15 (estimated)
Study Completion 2026-08-15 (estimated)
Updated on ClinicalTrials.gov 2026-05-14